Sleep Apnea Devices Market Size & Share 2026-2035

Sleep Apnea Devices Market Analysis

Based on product, the sleep apnea devices market is segmented into therapeutics and diagnostics. The therapeutics segment accounted for a dominating share of 66.3% in 2025. Increasing comorbidities (hypertension, diabetes, CVD) is anticipated to fuel the segmental growth. The segment is expected to reach USD 11.9 billion by 2035, growing at a CAGR of 6.8% during the forecast period.

• The ongoing development of new technologies for treating sleep disorders has provided patients with greater comfort and improved success rates in treating their sleep disorders. The modern advanced CPAP and BiPAP machines come with features such as quieter motors, auto-adjusting pressures, humidifiers, smartphone interface capability, and other new features that increase treatment compliance and improve long-term success rates of therapy for patients.
• Due to the growing trend towards providing therapy for sleep apnea patients in the comfort and safety of their own homes and various modern therapeutic devices being compatible with web-based/cloud technology and/or mobile applications, physicians can now have the ability to remotely monitor patient compliance.  This will improve treatment outcomes while making it as easy as possible for patients to comply with prescribed therapies because they are able to provide the required monitoring data to the physician almost instantly.
• In addition, hospitals, sleep labs, and respiratory care facilities are now placing a greater importance on investing in cutting-edge technologies to help treat patients more effectively. Many financial resources are now being spent on expanding sleep medicine departments and/or advanced respiratory therapy services within healthcare systems. These resources are being utilized to support the development of advanced therapeutic devices used in managing sleep apnea patients.
• The diagnostics segment held a significant share in the sleep apnea devices market with revenue of USD 3.1 billion in 2025. Healthcare providers are increasingly working toward identifying previously undiagnosed cases of sleep disorders; therefore, there is an increase in the demand for diagnostic tools such as polysomnography (PSG) and home sleep apnea testing devices.
• Various educational initiatives and digital health campaigns are focused on increasing awareness about sleep disorders and their associated health risks. Further, programs geared to promote early detection, such as the National Healthy Sleep Awareness Project, are encouraging more individuals to get sleep study tests performed on them.
• Moreover, HSAT devices allow patients to complete their own sleep studies in their place of comfort at home instead of visiting a hospital for an overnight stay using a PSG system. The demand for portable HSAT devices continues to increase among consumers because of the comfort factor associated with using these devices compared to using a PSG system in the hospital. Therefore, increased consumer acceptance of HSAT devices may have a significant impact on the diagnostic segment for sleep disorders.

Based on end use, the sleep apnea devices market is segmented into home care settings and individuals and sleep laboratories and hospitals. The home care settings and individuals segment dominates the market with the revenue of around USD 5.5 billion in 2025.

• Patients are increasingly managing sleep apnea therapy independently at home rather than relying on hospital-based care. User-friendly devices with simple interfaces allow individuals to start and manage treatment with minimal clinical supervision. This convenience improves therapy continuity and patient independence.
• Additionally, many providers now offer subscription or rental models for sleep apnea devices in home care settings. These programs include regular mask replacements, device maintenance, and remote technical support. Such services reduce the financial burden of upfront device purchase. This model is further accelerating the number of patients undergoing treatment in home care settings.
• The sleep laboratories and hospitals segment is projected to expand at 6.3% CAGR to reach USD 7 billion by 2035. This segment holds substantial growth potential, driven by the rising prevalence of obstructive sleep apnea and increasing demand for clinically supervised diagnosis and treatment.
• Sleep labs provide comprehensive polysomnography (PSG) testing, which remains the gold standard for diagnosing complex sleep disorders, especially in patients with comorbidities such as cardiovascular disease or obesity.
• Further, hospitals and specialty clinics are expanding sleep centers and integrating advanced diagnostic equipment, such as multi-channel PSG systems and cardiorespiratory monitoring devices, to support accurate diagnosis and personalized therapy.

 North America Sleep Apnea Devices Market

The North America sleep apnea devices industry accounted for a majority share of 45.1% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. sleep apnea devices industry was valued at USD 3.9 billion in 2025, up from USD 3.7 billion in 2024. Improved reimbursement policies in the country is anticipated to fuel the market growth.

• The region is witnessing a strong shift toward home sleep apnea testing as a convenient alternative to in-lab sleep studies. Home diagnostic devices allow patients to monitor sleep patterns and breathing disturbances in their own environment. This approach reduces diagnostic costs and improves accessibility for patients.
• Healthcare systems in the U.S. and Canada offer reimbursement for sleep apnea diagnosis and therapy under private insurance and government healthcare programs. Coverage for CPAP devices, diagnostic testing, and follow-up therapy is further encouraging patients to undergo treatment.

Europe Sleep Apnea Devices Market

Europe accounted for a significant share of the global sleep apnea devices industry and was valued at USD 2.4 billion in 2025.

• Europe’s rapidly aging population is leading to a growing prevalence of sleep apnea, with data from Eurostat showing that the portion of the European Union population 65+ years old grew to 21.1% in 2022 and will be higher in the future. Along with a higher risk of respiratory problems, cardiovascular disease, and disrupted sleep experiences in older individuals are driving the need for more sleep apnea diagnoses and treatments throughout Europe.

• In addition, many European healthcare systems are putting a major emphasis on patient safety and medical device safety through clearly defined regulatory guidelines. In particular, regulations put in place through the European Union Medical Device Regulation (EU MDR) further promote adoption of newer, clinically proven sleep apnea machines or devices.
• Finally, since many of the European healthcare systems are very focused on preventive care and detection of disease at an early stage, many doctors have started to use sleep studies to assess their patients who are at risk for cardiovascular disease or obesity.

Asia Pacific Sleep Apnea Devices Market

The Asia Pacific sleep apnea devices industry accounted for a substantial share of the market and was valued at USD 1.9 billion in 2025.

• There has been an increase in the prevalence of sleep apnea as a result of rapid urbanization and a growing rate of obesity in the Asia Pacific region. The United Nations has reported that urbanization in the Asia Pacific region is expected to increase to 56% by 2025 (54% as of 2022). Changes in lifestyle have had an impact on the increased incidence of sleep breathing disorders and, therefore, have increased demand for devices used to diagnose and treat sleep apnea.

• With price-sensitive markets throughout the Asia Pacific region, there is also a demand for portable and cost-effective sleep apnea devices.
• Furthermore, the private healthcare sector is expanding rapidly across Asia-Pacific, particularly in countries such as China, India, and Thailand, which is expected to push the industry's growth.

Latin America Sleep Apnea Devices Market

The Latin American sleep apnea devices industry is anticipated to exhibit remarkable growth during the analysis period.

• Changing dietary patterns and sedentary lifestyles are contributing to rising obesity rates in Latin American countries. Obesity, a major risk factor for obstructive sleep apnea, is leading to a growing number of individuals seeking diagnosis and treatment.

• Many countries in the region are expanding healthcare infrastructure through hospital modernization programs and the establishment of new diagnostic centers.
• Government agencies and healthcare providers are investing in advanced medical technologies to improve patient care. These investments are improving access to sleep apnea diagnostic services across the region.

Middle East and Africa Sleep Apnea Devices Market

The Middle East and Africa sleep apnea devices industry is expected to experience substantial growth over the analysis timeframe.

• Countries such as Saudi Arabia and the UAE are investing notably in modern healthcare infrastructure. New hospitals and specialty clinics are being established with advanced diagnostic capabilities. These developments are improving the availability of sleep disorder diagnosis and treatment services across the region.

• Several governments in the region are implementing healthcare reforms and national health programs aimed at improving disease diagnosis and management. These initiatives support the adoption of modern medical technologies, including sleep apnea diagnostic equipment.
• Further, Middle Eastern countries, particularly the UAE, are emerging as key medical tourism destinations for specialized healthcare services, thereby supporting the industry's growth.

Sleep Apnea Devices Market Share

The global sleep apnea device market is defined by a technologically advanced and fast‑evolving competitive environment, shaped by leading companies specializing in therapeutic PAP systems, oral appliance therapy, and connected sleep‑health platforms. Major players in this space leverage strong R&D capabilities, large global distribution networks, and digitally integrated solutions to strengthen their leadership across both home‑care and clinical sleep‑medicine segments. Companies such as ResMed Inc., Koninklijke Philips N.V., Fisher & Paykel Healthcare, SomnoMed Limited, and Asahi Kasei Corporation remain central to industry innovation. These organizations are at the forefront of developing next‑generation sleep therapy systems from cloud‑connected CPAP/APAP/BiPAP devices and advanced humidification technologies to precision‑engineered oral appliances tailored for CPAP‑intolerant patients. Their combined efforts support rising global demand driven by increasing OSA prevalence, improved diagnosis rates, and a shift toward personalized sleep‑care solutions. Other notable players in the sleep apnea device market include Natus, Apnea Sciences, Drive Medical, Breas Medical AB, Cadwell Industries, Inc., DynaFlex, Nihon Kohden Corporation, React Health, BPL Medical Technologies, and BMC Medical Co., Ltd. These organizations are actively expanding innovation across diagnostic and therapeutic sleep‑care technologies, contributing to the growth of both clinical and home‑based sleep apnea management.

Sleep Apnea Devices Market Companies

A few of the prominent players operating in the global sleep apnea devices industry include:

• Apnea Sciences

• Asahi KASEI
• BMC
• Cadwell
• Drive DeVilbiss
• DynaFlex
• FISHER & PAYKEL
• Glidewell
• natus
• NIHON KOHDEN
• Philips
• ResMed
• SomnoMed
• Teleflex
• WEINMANN

• ResMed

ResMed focuses on connected sleep therapy platforms, software-driven care management, continuous product innovation, and expanding digital health ecosystems to improve patient adherence and long-term outcomes.

• SomnoMed

SomnoMed emphasizes oral appliance therapy innovation, dentist-led distribution models, expanding clinical evidence, and geographic expansion to capture patients seeking CPAP alternatives.

• FISHER & PAYKEL

Fisher & Paykel prioritizes patient-centric mask design, humidification technology leadership, clinician partnerships, and steady geographic expansion within hospital and home sleep therapy segments.

Sleep Apnea Devices Industry News:

• In May 2025, ResMed acquired VirtuOx, a leading independent diagnostic testing facility specializing in sleep, respiratory, and cardiac diagnostics. This acquisition enhances ResMed’s virtual care capabilities by integrating at‑home diagnostic services into its ecosystem, enabling faster, more accessible, and more coordinated pathways to diagnosis and treatment for patients with sleep‑disordered breathing and related conditions.
• In July 2022, ARCHIMED has completed the acquisition of Natus Medical Incorporated (NTUS) in a landmark USD 1.1 billion take‑private transaction, marking a major strategic expansion for the firm’s growing healthcare portfolio. With this acquisition, ARCHIMED aimed to support Natus in strengthening its innovation pipeline, expanding its operational capabilities, and elevating its global market position within neurodiagnostics and patient‑monitoring technologies.

The sleep apnea devices market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Market, By Product

• Therapeutics
  • Positive airway pressure (PAP) devices
    • Continuous positive airway pressure (CPAP) devices
    • Automatic positive airway pressure (APAP) devices
    • Bilevel positive airway pressure (BiPAP) devices
  • Oral appliances
    • Mandibular advancement devices
    • Tongue-retaining devices
  • Adaptive servo-ventilation (ASV) devices
  • Airway clearance systems
  • Other therapeutic products
• Diagnostics
  • Home sleep testing (HST) devices
    • Type 2
    • Type 3
    • Type 4
  • Polysomnography (PSG) device
    • Clinical PSG devices
    • Ambulatory PSG devices
  • Actigraphy systems
  • Other diagnostic devices

Market, By End Use

• Home care settings and individuals
• Sleep laboratories and hospitals

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE